JNJ•benzinga•May 5, 2025 at 08:13 PM

Oric Pharmaceuticals Announces Clinical Trial Collaboration And Supply Agreement With Johnson & Johnson To Evaluate ORIC-114 In Combination With Subcutaneous Amivantamab For The First-Line Treatment Of NSCLC Patients With EGFR Exon 20 Insertion Mutations

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 5, 2025 by benzinga